SG11201805318SA - Formulations of phosphoramidate derivatives of nucleoside drugs - Google Patents
Formulations of phosphoramidate derivatives of nucleoside drugsInfo
- Publication number
- SG11201805318SA SG11201805318SA SG11201805318SA SG11201805318SA SG11201805318SA SG 11201805318S A SG11201805318S A SG 11201805318SA SG 11201805318S A SG11201805318S A SG 11201805318SA SG 11201805318S A SG11201805318S A SG 11201805318SA SG 11201805318S A SG11201805318S A SG 11201805318SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- formulations
- lochside
- edinburgh
- place
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522764.8A GB201522764D0 (en) | 2015-12-23 | 2015-12-23 | Formulations of phosphate derivatives |
| PCT/GB2016/054025 WO2017109491A1 (en) | 2015-12-23 | 2016-12-21 | Formulations of phosphoramidate derivatives of nucleoside drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805318SA true SG11201805318SA (en) | 2018-07-30 |
Family
ID=55311533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805318SA SG11201805318SA (en) | 2015-12-23 | 2016-12-21 | Formulations of phosphoramidate derivatives of nucleoside drugs |
| SG10202008554RA SG10202008554RA (en) | 2015-12-23 | 2016-12-21 | Formulations of phosphoramidate derivatives of nucleoside drugs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202008554RA SG10202008554RA (en) | 2015-12-23 | 2016-12-21 | Formulations of phosphoramidate derivatives of nucleoside drugs |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20180369266A1 (zh) |
| EP (1) | EP3393453A1 (zh) |
| JP (2) | JP6913095B2 (zh) |
| KR (1) | KR20180091919A (zh) |
| CN (1) | CN108697636A (zh) |
| AU (2) | AU2016375866B2 (zh) |
| BR (2) | BR112018012951B1 (zh) |
| CA (1) | CA3008751C (zh) |
| CL (1) | CL2018001672A1 (zh) |
| EA (2) | EA037320B1 (zh) |
| GB (1) | GB201522764D0 (zh) |
| HK (1) | HK1255108A1 (zh) |
| IL (1) | IL260008A (zh) |
| MA (1) | MA44117A (zh) |
| MX (2) | MX2018007794A (zh) |
| MY (1) | MY196741A (zh) |
| PH (1) | PH12018501341A1 (zh) |
| SA (1) | SA518391858B1 (zh) |
| SG (2) | SG11201805318SA (zh) |
| WO (1) | WO2017109491A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| HRP20211967T1 (hr) | 2011-03-01 | 2022-03-18 | NuCana plc | Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2'-deoksiuridina za uporabu u liječenju raka |
| NO3119794T3 (zh) | 2014-06-25 | 2018-03-10 | ||
| EP3683225A1 (en) | 2014-11-28 | 2020-07-22 | Nucana PLC | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| CN110840907B (zh) * | 2019-08-16 | 2022-11-25 | 南京医科大学 | 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途 |
| WO2023218202A2 (en) | 2022-05-12 | 2023-11-16 | NuCana plc | Cancer treatment |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011981A (es) | 1999-05-24 | 2003-09-04 | Sonus Pharma Inc | Vehiculo de emulsion para farmacos poco solubles. |
| GB0412866D0 (en) | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
| EP1845787B1 (en) | 2005-01-27 | 2015-04-15 | Erimos Pharmaceuticals LLC | Formulations for injection of catecholic butanes, including ndga compounds, into animals |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| US8492400B2 (en) | 2006-02-09 | 2013-07-23 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
| JP2012514657A (ja) * | 2009-01-09 | 2012-06-28 | ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド | ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体 |
| JP2012517443A (ja) | 2009-02-06 | 2012-08-02 | アールエフエス ファーマ，エルエルシー | 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ |
| KR101201956B1 (ko) | 2009-03-18 | 2012-11-19 | 신동헌 | 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑색종의 예방 또는 치료용 약학적 조성물 |
| CN102421293A (zh) | 2009-03-20 | 2012-04-18 | 艾丽奥斯生物制药有限公司 | 取代的核苷和核苷酸类似物 |
| AP3584A (en) | 2010-09-22 | 2016-02-09 | Alios Biopharma Inc | Substituted nucleotide analogs |
| HRP20211967T1 (hr) | 2011-03-01 | 2022-03-18 | NuCana plc | Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2'-deoksiuridina za uporabu u liječenju raka |
| WO2013070887A1 (en) | 2011-11-10 | 2013-05-16 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections |
| US9107943B2 (en) | 2012-01-20 | 2015-08-18 | Aratana Therapeutics Nv | Eye drop composition |
| US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| CA2903769A1 (en) | 2013-03-11 | 2014-10-09 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| NO3119794T3 (zh) * | 2014-06-25 | 2018-03-10 | ||
| EP3683225A1 (en) * | 2014-11-28 | 2020-07-22 | Nucana PLC | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
-
2015
- 2015-12-23 GB GBGB1522764.8A patent/GB201522764D0/en not_active Ceased
-
2016
- 2016-12-21 JP JP2018532773A patent/JP6913095B2/ja active Active
- 2016-12-21 EP EP16822242.0A patent/EP3393453A1/en active Pending
- 2016-12-21 BR BR112018012951-8A patent/BR112018012951B1/pt active IP Right Grant
- 2016-12-21 EA EA201891471A patent/EA037320B1/ru unknown
- 2016-12-21 WO PCT/GB2016/054025 patent/WO2017109491A1/en active Application Filing
- 2016-12-21 KR KR1020187020169A patent/KR20180091919A/ko active Search and Examination
- 2016-12-21 MA MA044117A patent/MA44117A/fr unknown
- 2016-12-21 MY MYPI2018001014A patent/MY196741A/en unknown
- 2016-12-21 BR BR122023000551-1A patent/BR122023000551B1/pt active IP Right Grant
- 2016-12-21 SG SG11201805318SA patent/SG11201805318SA/en unknown
- 2016-12-21 CN CN201680082281.7A patent/CN108697636A/zh active Pending
- 2016-12-21 US US16/065,402 patent/US20180369266A1/en not_active Abandoned
- 2016-12-21 MX MX2018007794A patent/MX2018007794A/es unknown
- 2016-12-21 CA CA3008751A patent/CA3008751C/en active Active
- 2016-12-21 AU AU2016375866A patent/AU2016375866B2/en active Active
- 2016-12-21 SG SG10202008554RA patent/SG10202008554RA/en unknown
- 2016-12-21 EA EA202190058A patent/EA202190058A1/ru unknown
-
2018
- 2018-06-13 IL IL260008A patent/IL260008A/en unknown
- 2018-06-20 CL CL2018001672A patent/CL2018001672A1/es unknown
- 2018-06-21 PH PH12018501341A patent/PH12018501341A1/en unknown
- 2018-06-21 SA SA518391858A patent/SA518391858B1/ar unknown
- 2018-06-22 MX MX2021010601A patent/MX2021010601A/es unknown
- 2018-11-08 HK HK18114263.1A patent/HK1255108A1/zh unknown
-
2021
- 2021-04-15 US US17/231,606 patent/US11786544B2/en active Active
- 2021-07-09 JP JP2021113985A patent/JP2021165310A/ja active Pending
-
2022
- 2022-08-02 AU AU2022211797A patent/AU2022211797B2/en active Active
-
2023
- 2023-09-22 US US18/371,865 patent/US20240082287A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805318SA (en) | Formulations of phosphoramidate derivatives of nucleoside drugs | |
| SG11201810018TA (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201810605UA (en) | Selectively altering microbiota for immune modulation | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201906223TA (en) | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201811316YA (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201810146SA (en) | Adenosine derivatives for use in the treatment of cancer | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201805184TA (en) | Combination therapy | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones |